30th Nov 2005 07:03
Hikma Pharmaceuticals Plc30 November 2005 30 November 2005 Hikma Pharmaceuticals plc Over Allotment Option Not for release, publication or distribution in, or into, the United States,directly or indirectly, Canada, Australia or Japan Announcement of Exercise of Over-Allotment Option Hikma Pharmaceuticals plc ("Hikma" or the "Company") announces that, inconnection with its initial public offering of Ordinary Shares (the "GlobalOffer"), Merrill Lynch International, as stabilising manager, has given noticeto exercise the over-allotment option in respect of 260,456 Ordinary Shares inthe Company. The Company will receive gross proceeds of £755,322.40 arising fromthe exercise of the over-allotment option. Including the exercise of the over-allotment option, the gross proceeds of theGlobal Offer will be £149.56 million, comprising 51.57 million Ordinary Shares. This announcement may not be distributed, directly or indirectly, in or into theUnited States, Canada, Australia or Japan. This announcement does not constituteor form part of an offer to sell or issue, or any solicitation of an offer tobuy or subscribe for, any securities referred to herein. The Global Offer andthe distribution of this announcement and other information in connection withthe Global Offer in certain jurisdictions may be restricted by law and personsinto whose possession any document or other information referred to herein comesshould inform themselves about and observe any such restriction. Any failure tocomply with these restrictions may constitute a violation of the securities lawsof any such jurisdiction. The securities mentioned herein have not been, and will not be, registered underthe U.S. Securities Act of 1933 (the "Securities Act"), and may not be offeredor sold in the United States (as such term is defined in Regulation S under theSecurities Act) unless they are registered under the Securities Act or pursuantto an exemption from registration. No public offer of the ordinary shares isbeing made in the United States. ENQUIRIES: Hikma Pharmaceuticals PLCBassam Kanaan (Chief Financial Officer) +962 6 580 2900 BrunswickJon Coles +44 207 404 5959Wendel Verbeek Merrill Lynch InternationalRichard Girling +44 20 7628 1000John PlaxtonMichael FrostKen Lim This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals